This is supported by a post-hoc of the "Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial” that found elevated renin levels in patients with catecholamine-resistant distributive shock9, and when Ang II was administered, serum renin levels decreased, which supports that the use of Ang II can suppress serum renin levels. This evidence concerns the gene REN and Shock.